Allen Peter J, Kuk Deborah, Castillo Carlos Fernandez-Del, Basturk Olca, Wolfgang Christopher L, Cameron John L, Lillemoe Keith D, Ferrone Cristina R, Morales-Oyarvide Vicente, He Jin, Weiss Matthew J, Hruban Ralph H, Gönen Mithat, Klimstra David S, Mino-Kenudson Mari
*Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY †Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY ‡Department of Surgery, Massachusetts General Hospital, Boston, MA §Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY ¶Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD ||Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD **Department of Pathology, Massachusetts General Hospital, Boston, MA.
Ann Surg. 2017 Jan;265(1):185-191. doi: 10.1097/SLA.0000000000001763.
The aim of this study was to evaluate and validate the proposed 8th edition American Joint Committee on Cancer (AJCC) system for T and N staging of pancreatic adenocarcinoma.
Investigators have questioned the clinical relevance and reproducibility of previous AJCC staging for pancreatic adenocarcinoma.
Prospective databases at Memorial Sloan Kettering (MSK), Massachusetts General Hospital (MGH), and Johns Hopkins Hospital (JHH) were queried for patients who had undergone resection for pancreatic adenocarcinoma. Patients who underwent a margin-negative (R0) resection, and who had previously undergone pathologic review, were included. Patients were staged according to 7th edition AJCC criteria, as well as the proposed 8th edition system that includes different definitions of tumor size (T) and nodal status (N). The dataset was randomly split into training and test sets.
Two thousand three hundred eighteen patients were identified who met inclusion criteria. Recursive partitioning on the training set (n = 1551) identified statistically appropriate cutoffs for tumor size (<2.2 cm, ≥4.8 cm,) and nodal status (no positive nodes, 1 to 3 positive nodes, ≥4 positive nodes) that supported the proposed 8th edition changes. Median survival in patients staged as T3, N0 by the 7th edition definitions was different between institutions (median Center 1, 24 mo; Center 2, 37 mo; Center 3, 29 mo; P = 0.054). This difference was not observed when patients were staged as T3, N0 by 8th edition criteria. Stage, and stage-specific outcome (7th edition), on the test set revealed a predominance of patients (68%) within the IIB subgroup, and a concordance probability estimate (CPE) of 0.57 for stage-specific survival. When assessed with 8th edition criteria, no stage subgroup had a majority of patients, and the CPE was 0.58.
The proposed 8th edition changes for T and N classification were statistically valid and may allow a more reproducible system of T staging. This system also stratifies patients more evenly across stages without sacrificing prognostic accuracy.
本研究旨在评估和验证美国癌症联合委员会(AJCC)提议的第8版胰腺腺癌T和N分期系统。
研究人员对既往AJCC胰腺腺癌分期的临床相关性和可重复性提出质疑。
查询纪念斯隆凯特琳癌症中心(MSK)、麻省总医院(MGH)和约翰霍普金斯医院(JHH)的前瞻性数据库,以获取接受过胰腺腺癌切除术的患者。纳入接受切缘阴性(R0)切除术且之前接受过病理检查的患者。根据第7版AJCC标准以及提议的第8版系统(包括不同的肿瘤大小(T)和淋巴结状态(N)定义)对患者进行分期。数据集被随机分为训练集和测试集。
确定了2318例符合纳入标准的患者。对训练集(n = 1551)进行递归划分,确定了肿瘤大小(<2.2 cm,≥4.8 cm)和淋巴结状态(无阳性淋巴结、1至3个阳性淋巴结、≥4个阳性淋巴结)的统计学合适临界值,支持提议的第8版更改。按照第7版定义分期为T3、N0的患者,各机构间的中位生存期不同(中心1中位生存期为24个月;中心2为37个月;中心3为29个月;P = 0.054)。当按照第8版标准将患者分期为T3、N0时,未观察到这种差异。测试集上的分期及特定分期结局(第7版)显示,IIB亚组内患者占多数(68%),特定分期生存的一致性概率估计(CPE)为0.57。按照第8版标准评估时,没有一个分期亚组患者占多数,CPE为0.58。
提议的第8版T和N分类更改在统计学上有效,可能会产生一个更具可重复性的T分期系统。该系统还能在不牺牲预后准确性的情况下,更均匀地对各分期患者进行分层。